Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment

Zelira Therapeutics Ltd ZLD ZLDAF, a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD).

Cantheon Capital LLC agreed to provide an initial $8.6 million in funding to Zelira to conduct FDA clinical trials.

The investment represents approximately 25% of the total $35 million needed to cover the U.S. Food Drug Administration trial costs.

See Also: Psychedelics Funding At Its Best - $1.5M Destined To Psilocin Clinical Trials In Australia

"As global investors in this space, we are excited to have the opportunity to fund a product that already has a considerable amount of real-world data for safety and efficacy, with millions of doses having been dispensed to patients over several years before the start of formal FDA clinical trials," Cantheon's Aaron Ray said.
Additionally, Zelira will get 55% equity ownership of a special-purpose vehicle while cash investors get a 45% equity interest.

Zelira is partnering with a research organization, iNGENū, for what the company hopes will be "a successful clinical trial" that results in the U.S. FDA approval of HOPE 1 as "a frontline solution for patients living with ASD,” Zelira Managing Director Oludare Odumosu explained.

The Benzinga Cannabis Capital Conference Is Back!

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A start, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo: Courtesy Of Rick Proctor On Unsplash